Do Standard Toxicology Parameters Match Clinical Needs for Immune Check-point Inhibitors in Liver Cancer Therapy?

Professor of medicine, Gastroenterology and Endocrinology, University Medical Center Göttingen, Göttingen, Germany. Executive Chief Editor of Hepatoma Research.

Doctor, Phase 1 Clinical Trials QA Coordinator - Ospedali Riuniti Ancona - Umberto I G.M. Lancisi G. Salesi, Clinical Trial Quality Assurance, United Hospitals of Ancona, Ancona, Marches, Italy.

Professor of medicine, a former president of the American Association for the Study of Liver Disease, Gastroenterologist in Berwyn, Rush University Medical Center, Berwyn, Illinois, USA.
Topic: The use of systemic therapy for HCC relapse post transplantation

Director emeritus of the Department of Gastroenterology and Hepatology, University of Essen, Essen, Germany.
Ethics committee of the European Association for the Study of the Liver (EASL). Associate Editor of Hepatoma Research.
Topic: How to screen and diagnose liver function in patients with chronic liver disease including liver cirrhosis

Director Gastroenterology, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy. Associate Editor of Hepatoma Research.
Topic: "Special" problems in the modern treatment of HCC in cirrhotic patients

Consultant Medical Oncologist, Department of Oncology & London Sarcoma Service, University College London Hospitals UCLH NHS, London, UK.
Topic: Therpaeutic aims of the oncologist: between cancer control and quality of life

Doctor, Phase 1 Clinical Trials QA Coordinator - Ospedali Riuniti Ancona - Umberto I G.M. Lancisi G. Salesi, Clinical Trial Quality Assurance, United Hospitals of Ancona, Ancona, Marches, Italy.
Topic: Preventive actions for safety in biological therapies